Phase 1/2a, Double-blind, Placebo-controlled Study with an Open-label Extension of Ropinirole Hydrochloride Extended-Release Tablets -Explorative Assessment of the Safety, Tolerability, and Efficacy after Oral Treatment in Patients with Amyotrophic Lateral Sclerosis (ALS)
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 16 Sep 2019
Price : $35 *
At a glance
- Drugs Ropinirole (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- 13 Sep 2019 Status changed from suspended to active, no longer recruiting.
- 17 Apr 2019 Status changed from not yet recruiting to suspended.
- 03 Dec 2018 New trial record